{
    "clinical_study": {
        "@rank": "270",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 10, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04324463"
        },
        "id_info": {
            "org_study_id": "PHRI.ACT.COVID19",
            "nct_id": "NCT04324463"
        },
        "brief_title": "Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial",
        "acronym": "ACT COVID19",
        "official_title": "Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial",
        "sponsors": {
            "lead_sponsor": {
                "agency": "Population Health Research Institute",
                "agency_class": "Other"
            }
        },
        "source": "Population Health Research Institute",
        "oversight_info": {
            "has_dmc": "Yes",
            "is_fda_regulated_drug": "No",
            "is_fda_regulated_device": "No",
            "is_us_export": "No"
        },
        "brief_summary": {
            "textblock": "ACT is a randomized clinical trial to assess therapies to reduce the clinical progression of\n      COVID-19."
        },
        "detailed_description": {
            "textblock": "The ACT COVID-19 program consists of two parallel trials evaluating azithromycin and\n      chloroquine therapy (ACT) versus usual care in outpatients and inpatients who have tested\n      positive for COVID-19. The trial is an open-label, parallel group, randomized controlled\n      trial with an adaptive design. Adaptive design features include adaptive intervention arms\n      and adaptive sample size based on new and emerging data."
        },
        "overall_status": "Not yet recruiting",
        "start_date": {
            "@type": "Anticipated",
            "#text": "April 1, 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "December 31, 2020"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "September 30, 2020"
        },
        "phase": "Phase 3",
        "study_type": "Interventional",
        "has_expanded_access": "No",
        "study_design_info": {
            "allocation": "Randomized",
            "intervention_model": "Parallel Assignment",
            "intervention_model_description": "Open-label, parallel group randomized controlled trial",
            "primary_purpose": "Treatment",
            "masking": "None (Open Label)"
        },
        "primary_outcome": [
            {
                "measure": "Outpatients: Hospital Admission or Death",
                "time_frame": "Up to 6 weeks post randomization",
                "description": "In outpatients with COVID-19, the occurrence of hospital admission or death"
            },
            {
                "measure": "Inpatients: Invasive mechanical ventilation or mortality",
                "time_frame": "Up to 6 weeks post randomization",
                "description": "Patients intubated or requiring imminent intubation at the time of randomization will only be followed for the primary outcome of death."
            }
        ],
        "number_of_arms": "2",
        "enrollment": {
            "@type": "Anticipated",
            "#text": "1500"
        },
        "condition": [
            "Coronavirus",
            "Severe Acute Respiratory Syndrome"
        ],
        "arm_group": [
            {
                "arm_group_label": "Azithromycin and Chloroquine Therapy (ACT)",
                "arm_group_type": "Experimental",
                "description": "Chloroquine (Adults with a bodyweight \u2265 50 kg: 500 mg twice daily for 7 days; Adults with a bodyweight < 50 kg: 500 mg twice daily on days 1 and 2, followed by 500 mg once daily for days 3-7), plus Azithromycin (500 mg on day 1 followed by 250 mg daily for 4 days)"
            },
            {
                "arm_group_label": "Standard of Care",
                "arm_group_type": "No Intervention",
                "description": "No constraints for treating physicians on the therapies within the standard of care arm. All key co-interventions will be documented."
            }
        ],
        "intervention": [
            {
                "intervention_type": "Drug",
                "intervention_name": "Azithromycin",
                "description": "oral medication",
                "arm_group_label": "Azithromycin and Chloroquine Therapy (ACT)"
            },
            {
                "intervention_type": "Drug",
                "intervention_name": "Chloroquine",
                "description": "oral medication",
                "arm_group_label": "Azithromycin and Chloroquine Therapy (ACT)"
            }
        ],
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u2265 18 years of age\n\n          -  Informed consent\n\n          -  COVID-19 confirmed by established testing\n\n        Exclusion Criteria:\n\n          -  Known glucose-6-phosphate dehydrogenase (G6PD) deficiency\n\n          -  Contra-indication to chloroquine or azithromycin\n\n          -  Already receiving chloroquine or azithromycin"
            },
            "gender": "All",
            "minimum_age": "18 Years",
            "maximum_age": "N/A",
            "healthy_volunteers": "No"
        },
        "overall_official": [
            {
                "last_name": "Richard Whitlock, MD PhD",
                "role": "Principal Investigator",
                "affiliation": "Population Health Research Institute"
            },
            {
                "last_name": "Emilie Belley-Cote, MD PhD",
                "role": "Principal Investigator",
                "affiliation": "Population Health Research Institute"
            }
        ],
        "overall_contact": {
            "last_name": "ACT COVID-19 Study Coordinator",
            "phone": "905-297-3479",
            "email": "ACT.ProjectTeam@PHRI.ca"
        },
        "location": {
            "facility": {
                "name": "Hamilton Health Sciences",
                "address": {
                    "city": "Hamilton",
                    "state": "Ontario",
                    "zip": "L8L2X2",
                    "country": "Canada"
                }
            },
            "contact": {
                "last_name": "ACT COVID-19 Study Coordinator",
                "email": "ACT.ProjectTeam@PHRI.ca"
            }
        },
        "location_countries": {
            "country": "Canada"
        },
        "verification_date": "March 2020",
        "study_first_submitted": "March 25, 2020",
        "study_first_submitted_qc": "March 25, 2020",
        "study_first_posted": {
            "@type": "Actual",
            "#text": "March 27, 2020"
        },
        "last_update_submitted": "March 25, 2020",
        "last_update_submitted_qc": "March 25, 2020",
        "last_update_posted": {
            "@type": "Actual",
            "#text": "March 27, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        },
        "keyword": [
            "COVID-19",
            "chloroquine",
            "azithromycin",
            "coronavirus"
        ],
        "condition_browse": {
            "mesh_term": [
                "Coronavirus Infections",
                "Severe Acute Respiratory Syndrome"
            ]
        },
        "intervention_browse": {
            "mesh_term": [
                "Chloroquine",
                "Chloroquine diphosphate"
            ]
        },
        "patient_data": {
            "sharing_ipd": "Undecided"
        }
    }
}